Niox Group PLC
LSE:NIOX

Watchlist Manager
Niox Group PLC Logo
Niox Group PLC
LSE:NIOX
Watchlist
Price: 61.4 GBX -2.85%
Market Cap: 244.4m GBX
Have any thoughts about
Niox Group PLC?
Write Note

Niox Group PLC
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Niox Group PLC
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Niox Group PLC
LSE:NIOX
Selling, General & Administrative
-ÂŁ19.9m
CAGR 3-Years
5%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Selling, General & Administrative
-$53.7m
CAGR 3-Years
-261%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Selling, General & Administrative
-$54.9m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Selling, General & Administrative
-$65.5m
CAGR 3-Years
-24%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Selling, General & Administrative
-ÂŁ144.5m
CAGR 3-Years
-47%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Selling, General & Administrative
-ÂŁ7m
CAGR 3-Years
3%
CAGR 5-Years
37%
CAGR 10-Years
-24%
No Stocks Found

Niox Group PLC
Glance View

Market Cap
260.4m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.

NIOX Intrinsic Value
48.28 GBX
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Niox Group PLC's Selling, General & Administrative?
Selling, General & Administrative
-19.9m GBP

Based on the financial report for Jun 30, 2024, Niox Group PLC's Selling, General & Administrative amounts to -19.9m GBP.

What is Niox Group PLC's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
17%

Over the last year, the Selling, General & Administrative growth was -9%. The average annual Selling, General & Administrative growth rates for Niox Group PLC have been 5% over the past three years , 17% over the past five years .

Back to Top